|
1
|
Forde PM, Spicer J, Lu S, Provencio M,
Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson
SJ, et al: Neoadjuvant nivolumab plus chemotherapy in resectable
lung cancer. N Engl J Med. 386:1973–1985. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wakelee H, Liberman M, Kato T, Tsuboi M,
Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, et al:
Perioperative pembrolizumab for Early-stage non-small-cell lung
cancer. N Engl J Med. 389:491–503. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tsuboi M, Herbst RS, John T, Kato T, Majem
M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, et al: Overall
survival with osimertinib in resected EGFR-Mutated NSCLC. N Engl J
Med. 389:137–147. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Felip E, Altorki N, Zhou C, Csőszi T,
Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A,
Kenmotsu H, et al: Adjuvant atezolizumab after adjuvant
chemotherapy in resected stage IB-IIIA non-small-cell lung cancer
(IMpower010): A randomised, multicentre, open-label, phase 3 trial.
Lancet. 398:1344–1357. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mountzios G, Remon J, Hendriks LEL,
Garcia-Campelo R, Rolfo C, Van Schil P, Forde PM, Besse B, Subbiah
V, Reck M, et al: Immune-checkpoint inhibition for resectable
non-small-cell lung cancer-opportunities and challenges. Nat Rev
Clin Oncol. 20:664–677. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Frankell AM, Dietzen M, Al Bakir M, Lim
EL, Karasaki T, Ward S, Veeriah S, Colliver E, Huebner A, Bunkum A,
et al: The evolution of lung cancer and impact of subclonal
selection in TRACERx. Nature. 616:525–533. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Martínez-Ruiz C, Black JRM, Puttick C,
Hill MS, Demeulemeester J, Larose Cadieux E, Thol K, Jones TP,
Veeriah S, Naceur-Lombardelli C, et al: Genomic-transcriptomic
evolution in lung cancer and metastasis. Nature. 616:543–552. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Al Bakir M, Huebner A, Martínez-Ruiz C,
Grigoriadis K, Watkins TBK, Pich O, Moore DA, Veeriah S, Ward S,
Laycock J, et al: The evolution of non-small cell lung cancer
metastases in TRACERx. Nature. 616:534–542. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Black JRM, Bartha G, Abbott CW, Boyle SM,
Karasaki T, Li B, Chen R, Harris J, Veeriah S, Colopi M, et al:
Ultrasensitive ctDNA detection for preoperative disease
stratification in early-stage lung adenocarcinoma. Nat Med.
31:70–76. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yap TA, Manning HC, Sapra P, Mills GB and
O'Connor MJ: Targeting genomic instability in cancer. Cell.
189:2278–2306. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen X, Agustinus AS, Li J, DiBona M and
Bakhoum SF: Chromosomal instability as a driver of cancer
progression. Nat Rev Genet. 26:31–46. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pawlik P, Grigoriadis K, Bunkum A, Coggan
H, Frankell AM, Martínez-Ruiz C, Karasaki T, Huebner A, Rowan A,
Fisher J, et al: Clone copy number diversity is linked to survival
in lung cancer. Nature. 646:190–197. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu WT, Zalmas LP, Bailey C, Black JRM,
Martinez-Ruiz C, Pich O, Gimeno-Valiente F, Usaite I, Magness A,
Thol K, et al: TRACERx analysis identifies a role for FAT1 in
regulating chromosomal instability and whole-genome doubling via
Hippo signalling. Nat Cell Biol. 27:154–168. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baker TM, Lai S, Lynch AR, Lesluyes T, Yan
H, Ogilvie HA, Verfaillie A, Dentro S, Bowes AL, Pillay N, et al:
The history of chromosomal instability in Genome-Doubled tumors.
Cancer Discov. 14:1810–1822. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gimeno-Valiente F, Castignani C, Larose
Cadieux E, Mensah NE, Liu X, Chen K, Chervova O, Karasaki T, Weeden
CE, Richard C, et al: DNA methylation cooperates with genomic
alterations during non-small cell lung cancer evolution. Nat Genet.
57:2226–2237. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang J, Weiser NE, Wang G, Chowdhry S,
Curtis EJ, Zhao Y, Wong ITL, Marinov GK, Li R, Hanoian P, et al:
Enhancing transcription-replication conflict targets ecDNA-positive
cancers. Nature. 635:210–218. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hopkins JL, Lan L and Zou L: DNA repair
defects in cancer and therapeutic opportunities. Genes Dev.
36:278–293. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li Q, Qian W, Zhang Y, Hu L, Chen S and
Xia Y: A new wave of innovations within the DNA damage response.
Signal Transduct Target Ther. 8:3382023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Caswell DR, Gui P, Mayekar MK, Law EK,
Pich O, Bailey C, Boumelha J, Kerr DL, Blakely CM, Manabe T, et al:
The role of APOBEC3B in lung tumor evolution and targeted cancer
therapy resistance. Nat Genet. 56:60–73. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Díaz-Gay M, Zhang T, Hoang PH, Leduc C,
Baine MK, Travis WD, Sholl LM, Joubert P, Khandekar A, Zhao W, et
al: The mutagenic forces shaping the genomes of lung cancer in
never smokers. Nature. 644:133–144. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang T, Sang J, Hoang PH, Zhao W,
Rosenbaum J, Johnson KE, Klimczak LJ, McElderry J, Klein A, Wirth
C, et al: APOBEC affects tumor evolution and age at onset of lung
cancer in smokers. Nat Commun. 16:47112025. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Everall A, Tapinos A, Hawari A, Cornish
AJ, Sud A, Chubb D, Kinnersley B, Frangou A, Barquin M, Jung J, et
al: Comprehensive repertoire of the chromosomal alteration and
mutational signatures across 16 cancer types. Nat Genet.
58:570–581. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jamal-Hanjani M, Wilson GA, McGranahan N,
Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R,
Rosenthal R, et al: Tracking the evolution of non-small-cell lung
cancer. N Engl J Med. 376:2109–2121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Diossy M, Sztupinszki Z, Borcsok J,
Krzystanek M, Tisza V, Spisak S, Rusz O, Timar J, Csabai I,
Fillinger J, et al: A subset of lung cancer cases shows robust
signs of homologous recombination deficiency associated genomic
mutational signatures. NPJ Precis Oncol. 5:552021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yan X, Mischel P and Chang H:
Extrachromosomal DNA in cancer. Nat Rev Cancer. 24:261–273. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
De Zuani M, Xue H, Park JS, Dentro SC,
Seferbekova Z, Tessier J, Curras-Alonso S, Hadjipanayis A,
Athanasiadis EI, Gerstung M, et al: Single-cell and spatial
transcriptomics analysis of non-small cell lung cancer. Nat Commun.
15:43882024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lomakin A, Svedlund J, Strell C, Gataric
M, Shmatko A, Rukhovich G, Park JS, Ju YS, Dentro S, Kleshchevnikov
V, et al: Spatial genomics maps the structure, nature and evolution
of cancer clones. Nature. 611:594–602. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hertel A, Streuer A, Diehl S, Boch T,
Nörenberg D, Strittmatter A, Zöllner FG, Schoenberg SO, Hofmann WK,
Loges S, et al: Targeting tumoral heterogeneity in lung cancer: A
novel, CT-texture-guided targeted biopsy approach with exome
sequencing. NPJ Precis Oncol. 9:3422025. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hessey S, Bunkum A, Huebner A, Haase K,
Grigoriadis K, Naceur-Lombardelli C, Liu WK, Harrigan CF, Grieco C,
Marinelli D, et al: Evolutionary characterization of lung cancer
metastasis. Nature. 653:911–922. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Enfield KSS, Colliver E, Lee C, Magness A,
Moore DA, Sivakumar M, Grigoriadis K, Pich O, Karasaki T, Hobson
PS, et al: Spatial architecture of myeloid and T cells orchestrates
immune evasion and clinical outcome in lung cancer. Cancer Discov.
14:1018–1047. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mo CK, Liu J, Chen S, Storrs E, Targino da
Costa ALN, Houston A, Wendl MC, Jayasinghe RG, Iglesia MD, Ma C, et
al: Tumour evolution and microenvironment interactions in 2D and 3D
space. Nature. 634:1178–1186. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gerstberger S, Jiang Q and Ganesh K:
Metastasis. Cell. 186:1564–1579. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Goddard ET, Linde MH, Srivastava S, Klug
G, Shabaneh TB, Iannone S, Grzelak CA, Marsh S, Riggio AI, Shor RE,
et al: Immune evasion of dormant disseminated tumor cells is due to
their scarcity and can be overcome by T cell immunotherapies.
Cancer Cell. 42:119–134.e12. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Y, Liu F, Cai Q, Deng L, Ouyang Q,
Zhang XHF and Zheng J: Invasion and metastasis in cancer: Molecular
insights and therapeutic targets. Signal Transduct Target Ther.
10:572025. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dijkstra KK, Vendramin R, Karagianni D,
Witsen M, Gálvez-Cancino F, Hill MS, Foster KA, Barbè V, Angelova
M, Hynds RE, et al: Subclonal immune evasion in non-small cell lung
cancer. Cancer Cell. 43:1833–1849.e10. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang C, Li J, Chen J, Wang Z, Zhu G, Song
L, Wu J, Li C, Qiu R, Chen X, et al: Multi-omics analyses reveal
biological and clinical insights in recurrent stage I non-small
cell lung cancer. Nat Commun. 16:14772025. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chemi F, Rothwell DG, McGranahan N, Gulati
S, Abbosh C, Pearce SP, Zhou C, Wilson GA, Jamal-Hanjani M, Birkbak
NJ, et al: Pulmonary venous circulating tumor cell dissemination
before tumor resection and disease relapse. Nat Med. 25:1534–1539.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liang Y, Chen WM, Zhang Y and Li L:
Remodeling the tumor dormancy ecosystem to prevent recurrence and
metastasis. Signal Transduct Target Ther. 11:12026. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hong TH, Hwang S, Dasgupta A, Abbosh C,
Hung T, Bredno J, Walker J, Shi X, Milenkova T, Horn L, et al:
Clinical utility of Tumor-Naïve presurgical circulating tumor DNA
detection in Early-stage NSCLC. J Thorac Oncol. 19:1512–1524. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gale D, Heider K, Ruiz-Valdepenas A,
Hackinger S, Perry M, Marsico G, Rundell V, Wulff J, Sharma G,
Knock H, et al: Residual ctDNA after treatment predicts early
relapse in patients with early-stage non-small cell lung cancer.
Ann Oncol. 33:500–510. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tran HT, Heeke S, Sujit SJ, Vokes N, Zhang
J, Aminu M, Lam VK, Vaporciyan A, Swisher SG, Godoy MCB, et al:
Circulating tumor DNA and radiological tumor volume identify
patients at risk for relapse with resected, early-stage
non-small-cell lung cancer. Ann Oncol. 35:183–189. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sujit SJ, Aminu M, Karpinets TV, Chen P,
Saad MB, Salehjahromi M, Boom JD, Qayati M, George JM, Allen H, et
al: Enhancing NSCLC recurrence prediction with PET/CT habitat
imaging, ctDNA, and integrative radiogenomics-blood insights. Nat
Commun. 15:31522024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Herbst RS, John T, Grohé C, Goldman JW,
Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Dómine M, et al:
Molecular residual disease analysis of adjuvant osimertinib in
resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat
Med. 31:1958–1968. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Stetson D, Labrousse P, Russell H, Shera
D, Abbosh C, Dougherty B, Barrett JC, Hodgson D and Hadfield J:
Next-Generation molecular residual disease assays: Do we have the
tools to evaluate them properly? J Clin Oncol. 42:2736–2740. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Boukouris AE, Michaelidou K, Joosse SA,
Charpidou A, Mavroudis D, Syrigos KN and Agelaki S: A comprehensive
overview of minimal residual disease in the management of
early-stage and locally advanced non-small cell lung cancer. NPJ
Precis Oncol. 9:1782025. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Moding EJ, Nabet BY, Alizadeh AA and Diehn
M: Detecting liquid remnants of solid tumors: Circulating tumor DNA
minimal residual disease. Cancer Discov. 11:2968–2986. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zheng J, Qin C, Wang Q, Tian D and Chen Z:
Circulating tumour DNA-Based molecular residual disease detection
in resectable cancers: A systematic review and meta-analysis.
EBioMedicine. 103:1051092024. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Venkatesan S, Angelova M, Puttick C, Zhai
H, Caswell DR, Lu WT, Dietzen M, Galanos P, Evangelou K, Bellelli
R, et al: Induction of APOBEC3 exacerbates DNA replication stress
and chromosomal instability in early breast and lung cancer
evolution. Cancer Discov. 11:2456–2473. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Isozaki H, Sakhtemani R, Abbasi A, Nikpour
N, Stanzione M, Oh S, Langenbucher A, Monroe S, Su W, Cabanos HF,
et al: Therapy-induced APOBEC3A drives evolution of persistent
cancer cells. Nature. 620:393–401. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang X, Bai H, Zhang J, Wang Z, Duan J,
Cai H, Cao Z, Lin Q, Ding X, Sun Y, et al: Genetic intratumor
heterogeneity remodels the immune microenvironment and induces
immune evasion in brain metastasis of lung cancer. J Thorac Oncol.
19:252–272. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Drews RM, Hernando B, Tarabichi M, Haase
K, Lesluyes T, Smith PS, Morrill Gavarró L, Couturier DL, Liu L,
Schneider M, et al: A pan-cancer compendium of chromosomal
instability. Nature. 606:976–983. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chen K, Yang F, Shen H, Wang C, Li X,
Chervova O, Wu S, Qiu F, Peng D, Zhu X, et al: Individualized
tumor-informed circulating tumor DNA analysis for postoperative
monitoring of non-small cell lung cancer. Cancer Cell.
41:1749–1762.e6. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Stejskal P, Goodarzi H, Srovnal J, Hajdúch
M, van 't Veer LJ and Magbanua MJM: Circulating tumor nucleic
acids: Biology, release mechanisms, and clinical relevance. Mol
Cancer. 22:152023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Normanno N, Morabito A, Rachiglio AM,
Sforza V, Landi L, Bria E, Delmonte A, Cappuzzo F and De Luca A:
Circulating tumour DNA in early stage and locally advanced NSCLC:
Ready for clinical implementation? Nat Rev Clin Oncol. 22:215–231.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Black JRM, Karasaki T, Abbott CW, Li B,
Veeriah S, Al Bakir M, Liu WK, Huebner A, Martínez-Ruiz C, Pawlik
P, et al: Longitudinal ultrasensitive ctDNA monitoring for
high-resolution lung cancer risk prediction. Cell.
188:7083–7098.e18. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Schuurbiers MMF, Smith CG, Hartemink KJ,
Rintoul RC, Gale D, Monkhorst K, Mandos BLR, Paterson AL, van den
Broek D, Rosenfeld N, et al: Recurrence prediction using
circulating tumor DNA in patients with early-stage non-small cell
lung cancer after treatment with curative intent: A retrospective
validation study. PLoS Med. 22:e10045742025. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Qiu B, Guo W, Zhang F, Lv F, Ji Y, Peng Y,
Chen X, Bao H, Xu Y, Shao Y, et al: Dynamic recurrence risk and
adjuvant chemotherapy benefit prediction by ctDNA in resected
NSCLC. Nat Commun. 12:67702021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang JT, Liu SY, Gao W, Liu SYM, Yan HH,
Ji L, Chen Y, Gong Y, Lu HL, Lin JT, et al: Longitudinal
undetectable molecular residual disease defines potentially cured
population in localized Non-Small cell lung cancer. Cancer Discov.
12:1690–1701. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Tsui WHA, Jiang P and Lo YMD: Cell-free
DNA fragmentomics in cancer. Cancer Cell. 43:1792–1814. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Mathios D, Johansen JS, Cristiano S,
Medina JE, Phallen J, Larsen KR, Bruhm DC, Niknafs N, Ferreira L,
Adleff V, et al: Detection and characterization of lung cancer
using cell-free DNA fragmentomes. Nat Commun. 12:50602021.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
van 't Erve I, Alipanahi B, Lumbard K,
Skidmore ZL, Rinaldi L, Millberg LK, Carey J, Chesnick B, Cristiano
S, Portwood C, et al: Cancer treatment monitoring using cell-free
DNA fragmentomes. Nat Commun. 15:88012024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lo YMD, Han DSC, Jiang P and Chiu RWK:
Epigenetics, fragmentomics, and topology of cell-free DNA in liquid
biopsies. Science. 372:eaaw36162021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Pascual J, Attard G, Bidard FC, Curigliano
G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD,
Montagut C, et al: ESMO recommendations on the use of circulating
tumour DNA assays for patients with cancer: A report from the ESMO
Precision Medicine Working Group. Ann Oncol. 33:750–768. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Abbosh C, Frankell AM, Harrison T,
Kisistok J, Garnett A, Johnson L, Veeriah S, Colliver E, Moreau M,
Ward S, et al: Tracking early lung cancer metastatic dissemination
in TRACERx using ctDNA. Nature. 616:553–562. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Peri A, Salomon N, Wolf Y, Kreiter S,
Diken M and Samuels Y: The landscape of T cell antigens for cancer
immunotherapy. Nat Cancer. 4:937–954. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Litchfield K, Reading JL, Puttick C,
Thakkar K, Abbosh C, Bentham R, Watkins TBK, Rosenthal R, Biswas D,
Rowan A, et al: Meta-analysis of tumor- and T cell-intrinsic
mechanisms of sensitization to checkpoint inhibition. Cell.
184:596–614.e14. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Memon D, Schoenfeld AJ, Ye D, Fromm G,
Rizvi H, Zhang X, Keddar MR, Mathew D, Yoo KJ, Qiu J, et al:
Clinical and molecular features of acquired resistance to
immunotherapy in non-small cell lung cancer. Cancer Cell.
42:209–224.e9. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ricciuti B, Arbour KC, Lin JJ, Vajdi A,
Vokes N, Hong L, Zhang J, Tolstorukov MY, Li YY, Spurr LF, et al:
Diminished efficacy of programmed Death-(Ligand)1 inhibition in
STK11- and KEAP1-Mutant lung adenocarcinoma is affected by KRAS
mutation status. J Thorac Oncol. 17:399–410. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Ricciuti B and Garassino MC: Precision
immunotherapy for STK11/KEAP1-mutant NSCLC. J Thorac Oncol.
19:877–882. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Huang Y, Lu C, Wang H, Gu L, Fu YX and Li
GM: DNAJA2 deficiency activates cGAS-STING pathway via the
induction of aberrant mitosis and chromosome instability. Nat
Commun. 14:52462023. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Li J, Hubisz MJ, Earlie EM, Duran MA, Hong
C, Varela AA, Tsao JL, Petersson EJ, Lok BH, Modrek AS, et al:
Non-cell-autonomous cancer progression from chromosomal
instability. Nature. 620:1080–1088. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Heymach JV, Harpole D, Mitsudomi T, Taube
JM, Galffy G, Hochmair M, Winder T, Zukov R, Garbaos G, Gao S, et
al: Perioperative durvalumab for resectable Non-Small-Cell lung
cancer. N Engl J Med. 389:1672–1684. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Cascone T, Awad MM, Spicer JD, He J, Lu S,
Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, et al:
Perioperative nivolumab in resectable lung cancer. N Engl J Med.
390:1756–1769. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Sorin M, Prosty C, Ghaleb L, Nie K,
Katergi K, Shahzad MH, Dubé LR, Atallah A, Swaby A, Dankner M, et
al: Neoadjuvant Chemoimmunotherapy for NSCLC: A systematic review
and meta-analysis. JAMA Oncol. 10:621–633. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Vaccaro A, Rahal Z, Kadara H and Cascone
T: A roadmap to precision immunotherapy for Early-stage non-small
cell lung cancer. Cancer Discov. 15:884–889. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Xia L, Mei J, Kang R, Deng S, Chen Y, Yang
Y, Feng G, Deng Y, Gan F, Lin Y, et al: Perioperative ctDNA-Based
molecular residual disease detection for Non-Small cell lung
cancer: A prospective multicenter cohort study (LUNGCA-1). Clin
Cancer Res. 28:3308–3317. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zer A, Ahn MJ, Barlesi F, Bubendorf L, De
Ruysscher D, Garrido P, Gautschi O, Hendriks LE, Jänne PA, Kerr KM,
et al: Early and locally advanced non-small-cell lung cancer: ESMO
Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ann Oncol. 36:1245–1262. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Drew Y, Zenke FT and Curtin NJ: DNA damage
response inhibitors in cancer therapy: Lessons from the past,
current status and future implications. Nat Rev Drug Discov.
24:19–39. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Tsilingiri K, Chalari A, Christopoulou G,
Voutsina A, Constantoulakis P, Potaris K, Vamvakaris I, Hatzidaki
D, Zachou G, Vatsellas G, et al: Genomic scarring score predicts
the response to PARP inhibitors in non-small cell lung cancer. NPJ
Precis Oncol. 8:2912024. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Yap TA, Fontana E, Lee EK, Spigel DR,
Højgaard M, Lheureux S, Mettu NB, Carneiro BA, Carter L, Plummer R,
et al: Camonsertib in DNA damage response-deficient advanced solid
tumors: Phase 1 trial results. Nat Med. 29:1400–1411. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Yap TA, Tan DSP, Terbuch A, Caldwell R,
Guo C, Goh BC, Heong V, Noor NR, Bashir S, Drew Y, et al:
First-in-Human trial of the oral ataxia telangiectasia and
RAD3-Related (ATR) inhibitor BAY 1895344 in patients with advanced
solid tumors. Cancer Discov. 11:80–91. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Fukuda K, Takeuchi S, Arai S, Nanjo S,
Sato S, Kotani H, Kita K, Nishiyama A, Sakaguchi H, Ohtsubo K, et
al: Targeting WEE1 enhances the antitumor effect of KRAS-mutated
non-small cell lung cancer harboring TP53 mutations. Cell Rep Med.
5:1015782024. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Yap TA, LoRusso P, Miller RE, Kristeleit
R, Paulovich AG, McMorn S, Oplustil O'Connor L, Lombardi B,
Marco-Casanova P, Gangl ET, et al: The DNA-PK inhibitor AZD7648
alone or combined with pegylated liposomal doxorubicin in patients
with advanced cancer: Results of a first-in-human Phase I/IIa
study. Br J Cancer. 133:168–177. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
da Costa AABA, Chowdhury D, Shapiro GI,
D'Andrea AD and Konstantinopoulos PA: Targeting replication stress
in cancer therapy. Nat Rev Drug Discov. 22:38–58. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Besse B, Pons-Tostivint E, Park K, Hartl
S, Forde PM, Hochmair MJ, Awad MM, Thomas M, Goss G, Wheatley-Price
P, et al: Biomarker-directed targeted therapy plus durvalumab in
advanced non-small-cell lung cancer: A phase 2 umbrella trial. Nat
Med. 30:716–729. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Gray JE, Schenker M, Şendur MAN, Leonova
V, Kowalski D, Kato T, Orlova R, Yang JC, Langleben A, Pilz A, et
al: The Phase 3 KEYLYNK-006 study of pembrolizumab plus olaparib
versus pembrolizumab plus pemetrexed as maintenance therapy for
metastatic nonsquamous NSCLC. J Thorac Oncol. 20:219–232. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Hochmair M, Schenker M, Cobo Dols M, Kim
TM, Ozyilkan O, Smagina M, Leonova V, Kato T, Fedenko A, De Angelis
F, et al: Pembrolizumab with or without maintenance olaparib for
metastatic squamous NSCLC that responded to First-Line
pembrolizumab plus chemotherapy. J Thorac Oncol. 20:203–218. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Cleary JM, Aguirre AJ, Shapiro GI and
D'Andrea AD: Biomarker-guided development of DNA repair inhibitors.
Mol Cell. 78:1070–1085. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Bailey C, Pich O, Thol K, Watkins TBK,
Luebeck J, Rowan A, Stavrou G, Weiser NE, Dameracharla B, Bentham
R, et al: Origins and impact of extrachromosomal DNA. Nature.
635:193–200. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Hung KL, Yost KE, Xie L, Shi Q, Helmsauer
K, Luebeck J, Schöpflin R, Lange JT, Chamorro González R, Weiser
NE, et al: ecDNA hubs drive cooperative intermolecular oncogene
expression. Nature. 600:731–736. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Rami-Porta R, Nishimura KK, Giroux DJ,
Detterbeck FC, Asamura H, Goldstraw P, Crowley J, Chansky K,
Edwards J, Nicholson AG, et al: The international association for
the study of lung cancer lung cancer staging project: Proposals for
revision of the TNM stage groups in the forthcoming (Ninth) edition
of the TNM classification for lung cancer. J Thorac Oncol.
19:1007–1027. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Spicer JD, Cascone T, Wynes MW, Ahn MJ,
Dacic S, Felip E, Forde PM, Higgins KA, Kris MG, Mitsudomi T, et
al: Neoadjuvant and adjuvant treatments for early stage resectable
NSCLC: Consensus recommendations from the international association
for the study of lung cancer. J Thorac Oncol. 19:1373–1414. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wu YL, Dziadziuszko R, Ahn JS, Barlesi F,
Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, et al:
Alectinib in resected ALK-Positive Non-Small-Cell lung cancer. N
Engl J Med. 390:1265–1276. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Passaro A, Al Bakir M, Hamilton EG, Diehn
M, André F, Roy-Chowdhuri S, Mountzios G, Wistuba II, Swanton C and
Peters S: Cancer biomarkers: Emerging trends and clinical
implications for personalized treatment. Cell. 187:1617–1635. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Steele CD, Abbasi A, Islam SMA, Bowes AL,
Khandekar A, Haase K, Hames-Fathi S, Ajayi D, Verfaillie A, Dhami
P, et al: Signatures of copy number alterations in human cancer.
Nature. 606:984–991. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Biswas D, Liu YH, Herrero J, Wu Y, Moore
DA, Karasaki T, Grigoriadis K, Lu WT, Veeriah S, Naceur-Lombardelli
C, et al: Prospective validation of ORACLE, a clonal expression
biomarker associated with survival of patients with lung
adenocarcinoma. Nat Cancer. 6:86–101. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Groelly FJ, Fawkes M, Dagg RA, Blackford
AN and Tarsounas M: Targeting DNA damage response pathways in
cancer. Nat Rev Cancer. 23:78–94. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Wong IT, Yi H, Melillo B, Cravatt BF,
Chang HY and Mischel PS: Targeting extrachromosomal DNA in human
cancers. Nat Rev Drug Discov. 25:374–389. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Al-Rawi DH, Lettera E, Li J, DiBona M and
Bakhoum SF: Targeting chromosomal instability in patients with
cancer. Nat Rev Clin Oncol. 21:645–659. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Tan AC, Liao BC, Li M, Lee D, Uehara Y,
Thamlikitkul L, Zhang JT, Zheng M, Lee CK, Pavlakis N, et al:
Consensus statement on ctDNA minimal residual disease testing in
early stage NSCLC: A Delphi study by the Asian thoracic oncology
research group. J Thorac Oncol. 21:1036962026. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Karasaki T, Moore DA, Veeriah S,
Naceur-Lombardelli C, Toncheva A, Magno N, Ward S, Bakir MA,
Watkins TBK, Grigoriadis K, et al: Evolutionary characterization of
lung adenocarcinoma morphology in TRACERx. Nat Med. 29:833–845.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Malki Y, Zhou Q, Jiang P and Lo YMD: The
comings and goings of cell-free DNA: Biological and clinical
implications. Med. 7:1009262026. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Hayes DF: Defining clinical utility of
tumor biomarker tests: A Clinician's Viewpoint. J Clin Oncol.
39:238–248. 2021. View Article : Google Scholar : PubMed/NCBI
|
